A5072124665- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Computational Drug Discovery Methods
- Lung Cancer Treatments and Mutations
- Bioinformatics and Genomic Networks
- Melanoma and MAPK Pathways
- Lung Cancer Diagnosis and Treatment
- Cell Image Analysis Techniques
- 3D Printing in Biomedical Research
- Health and Medical Research Impacts
- Cancer Cells and Metastasis
- Brain Metastases and Treatment
- Cancer Research and Treatments
- Statistical Methods in Clinical Trials
- Artificial Intelligence in Healthcare and Education
- Biomedical and Engineering Education
- Bacteriophages and microbial interactions
Wellcome Sanger Institute
2024
University of Sheffield
2018-2021
Princess Margaret Cancer Centre
2021
Sheffield Teaching Hospitals NHS Foundation Trust
2021
High-throughput testing of drugs across molecular-characterised cell lines can identify candidate treatments and discover biomarkers. However, the cells’ response to a drug is typically quantified by summary statistic from best-fit dose-response curve, whilst neglecting uncertainty curve fit potential variability in raw readouts. Here, we model experimental variance using Gaussian Processes, subsequently, leverage estimates associated biomarkers with new Bayesian framework. Applied vitro...
Abstract Personalised medicine has predominantly focused on genetically altered cancer genes that stratify drug responses, but there is a need to objectively evaluate differential pharmacology patterns at subpopulation level. Here, we introduce an approach based unsupervised machine learning compare the pharmacological response relationships between 327 pairs of therapies. This integrated multiple measures identify subpopulations react differently inhibitors same or different targets...
Despite evidence for the superiority of twice-daily (BID) radiotherapy schedules, their utilization in practice remains logistically challenging. Hypofractionation (HFRT) is a commonly implemented alternative. We aim to compare outcomes and toxicities limited-stage small-cell lung cancer (LS-SCLC) patients treated with hypofractionated versus BID schedules. A bi-institutional retrospective cohort review was conducted LS-SCLC (45 Gy/30 fractions) or HFRT (40 Gy/15 schedules from 2007 2019....
Abstract Drug high-throughput screenings across large molecular-characterised cancer cell line panels enable the discovery of biomarkers, and thereby, precision medicine. The ability to experimentally generate drug response data has accelerated. However, this is typically quantified by a summary statistic from best-fit dose curve, whilst neglecting uncertainty curve fit potential variability in raw readouts. Here, we model experimental variance using Gaussian Processes, subsequently,...
Abstract Personalised medicine has predominantly focused on genetically-altered cancer genes that stratify drug responses, but there is a need to objectively evaluate differential pharmacology patterns at subpopulation level. Here, we introduce an approach based unsupervised machine learning compare the pharmacological response relationships between 327 pairs of therapies. This integrated multiple measures identify subpopulations react differently inhibitors same or different targets...
Purpose or ObjectiveThe PACIFIC trial showed a remarkable overall survival benefit with the adjuvant immune checkpoint inhibitor durvalumab after concomitant chemoradiotherapy (cCRT) for stage III non-small cell lung cancer (NSCLC).Inclusion criteria in study were performance status (PS) 0-1 and no progression cCRT.The therapy was initiated within 42 days last radiotherapy (RT) fraction.There statistically significant advantage of starting treatment early versus late days, emphasizing value...
Limited-stage (LS) small-cell lung cancer (SCLC) is defined as disease confined to a tolerable radiation portal without extrathoracic metastases. Despite clinical research over two decades, the prognosis of LS-SCLC patients remains poor. The current standard care for concurrent platinum-based chemotherapy with thoracic radiotherapy (RT). Widespread heterogeneity on optimal dose and fractionation regimen among physicians highlights logistical challenges administering BID regimens....